Długoterminowe wyniki leczenia farmakologicznego u pacjentów z nowo rozpoznaną ogniskową epilepsją i znaczenie czasu występowania napadów na początku choroby: Badanie obserwacyjne prospektywne
Long-term prognosis of pharmacotherapy in newly diagnosed focal epilepsy patients and the predictive value of baseline seizure timing: A prospective cohort study
W skrócie
Badanie analizowało ponad 500 pacjentów z nowo rozpoznaną ogniskową epilepsją przez co najmniej 3 lata, aby zrozumieć, jak dobrze leki działają i jakie czynniki mogą przewidzieć wynik leczenia. Okazało się, że połowa pacjentów reaguje dobrze na leki, a połowa ma trudności z ich skutecznym zwalczaniem napadów. Naukowcy znaleźli, że napady pojawiające się podczas czuwania, napady pojawiające się w seriach, status epilepticus na początku choroby oraz problemy ze snem są wskaźnikami, które mogą wskazywać na gorszą odpowiedź organizmu na leczenie.
Oryginalny abstract (angielski)
OBJECTIVE: Epilepsy is a highly heterogeneous neurological disorder with significant prognostic variability. Accurate long-term outcome prediction remains a clinical challenge. We investigated pharmacotherapeutic prognosis and key predictors, particularly baseline seizure timing, to guide individualized treatment. METHODS: This prospective cohort study consecutively enrolled newly diagnosed focal epilepsy patients from the epilepsy specialist clinic of the Department of Neurology in our hospital between September 2015 and September 2025. We applied the Cox proportional hazards regression model to analyze the association between baseline factors and prognosis to identify independent predictors. RESULTS: A total of 563 patients with ≥36-month follow-up (median = 48.0 months, interquartile range [IQR] = 36.0-78.0) were analyzed. Among them, 64.8% (365/563) achieved seizure freedom at least once (median = 27.0 months, 95% confidence interval [CI] = 22.5-31.5), and 35.9% (131/365) relapsed after seizure freedom; 25.4% (143/563) developed drug resistance, with 6.3% (9/143) later converting to drug-responsive status. At the end of follow-up, 50.8% (286/563) were classified as drug-responsive, 23.8% (134/563) as having drug-resistant epilepsy (DRE), and 25.4% (143/563) as having an undetermined prognosis. Among patients with drug-responsive epilepsy, 63.6% (182/286) achieved seizure freedom with monotherapy. Multivariate analysis identified baseline wake-related seizures (hazard ratio [HR] = 1.743, 95% CI = 1.101-2.760, p = .018), cluster seizures (HR = 2.630, 95% CI = 1.845-3.749, p < .001), status epilepticus (HR = 2.126, 95% CI = 1.394-3.242, p < .001), and sleep problems (HR = 1.740, 95% CI = 1.178-2.572, p = .005) as independent DRE risk factors. SIGNIFICANCE: This prospective large-sample study revealed the inherent complexity and dynamic nature of prognostic assessment in patients with newly diagnosed focal epilepsy. We identified independent prognostic predictors for this condition, first confirming baseline wake-related seizures as a predictor of poor prognosis to guide early risk stratification and personalized treatment.